Israel Institute of biological research (IIBM) isolated the monoclonal antibody in the quest for the treatment of Covid-19. Israel Country’s defense minister shared this news with media on Monday. IIBR briefed him “on a significant breakthrough in finding a Covid-19 Antidote for the coronavirus”
Defence Minister Naftali Bennett said the reporters “The “monoclonal neutralizing antibody” developed at the Israel Institute for Biological Research (IIBR) “can neutralize it (the disease-causing coronavirus) inside carriers’ bodies”.
The Covid-19 Antidote is derived by IIBR is Monoclonal; it means it is developed from a single recovered cell; thus it has potentially more potent value in yielding the treatment. The development of the antibody is completed, Bennet said that now they are moving for the next phase of animal testing.
IIBR Director Shmuel Shapira said that they are first gonna register this Covid-19 Antidote formula for patent and then they will connect international manufacturers for the mass production of the antibodies for commercial use.
Many companies and research laboratories are working for the development of the COVID-19 vaccine or antidote. Further research on antibodies may help to gain knowledge and information about the appropriate treatment methods for COVID-19.